James Quigley
Stock Analyst at Goldman Sachs
(1.66)
# 3,664
Out of 5,149 analysts
26
Total ratings
50%
Success rate
0.08%
Average return
Main Sectors:
Stocks Rated by James Quigley
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| NVO Novo Nordisk | Downgrades: Neutral | $63 → $41 | $38.18 | +7.39% | 2 | Mar 2, 2026 | |
| KYMR Kymera Therapeutics | Maintains: Overweight | $73 → $127 | $84.82 | +49.73% | 7 | Dec 9, 2025 | |
| NVS Novartis AG | Downgrades: Sell | $119 → $118 | $164.05 | -28.07% | 2 | Sep 12, 2025 | |
| SNY Sanofi | Initiates: Neutral | $65 | $46.16 | +40.81% | 1 | Mar 21, 2025 | |
| GRFS Grifols | Maintains: Neutral | $10 → $11 | $8.66 | +21.25% | 1 | Dec 5, 2023 | |
| GLPG Galapagos NV | Maintains: Equal-Weight | $42 → $40 | $33.41 | +19.72% | 10 | Aug 7, 2023 | |
| EVO Evotec SE | Upgrades: Overweight | $12 → $16 | $3.20 | +400.78% | 3 | Jun 23, 2023 |
Novo Nordisk
Mar 2, 2026
Downgrades: Neutral
Price Target: $63 → $41
Current: $38.18
Upside: +7.39%
Kymera Therapeutics
Dec 9, 2025
Maintains: Overweight
Price Target: $73 → $127
Current: $84.82
Upside: +49.73%
Novartis AG
Sep 12, 2025
Downgrades: Sell
Price Target: $119 → $118
Current: $164.05
Upside: -28.07%
Sanofi
Mar 21, 2025
Initiates: Neutral
Price Target: $65
Current: $46.16
Upside: +40.81%
Grifols
Dec 5, 2023
Maintains: Neutral
Price Target: $10 → $11
Current: $8.66
Upside: +21.25%
Galapagos NV
Aug 7, 2023
Maintains: Equal-Weight
Price Target: $42 → $40
Current: $33.41
Upside: +19.72%
Evotec SE
Jun 23, 2023
Upgrades: Overweight
Price Target: $12 → $16
Current: $3.20
Upside: +400.78%